Satyen Manikani has been elevated to Chief Portfolio Head – Global at Cipla, marking a significant milestone in his distinguished career in pharmaceutical strategy, portfolio management, and business development. Having joined Cipla in 2022 to strengthen the company’s India portfolio, Satyen will now lead the strategic development of Cipla’s global portfolio, driving long-term growth through innovation, portfolio optimization, and global market expansion.
A seasoned pharmaceutical leader with extensive expertise in strategy, portfolio management, in-licensing, and business development, Satyen has consistently delivered impactful portfolio strategies across leading healthcare organizations. His deep understanding of market dynamics, product lifecycle management, and commercial strategy has enabled organizations to build competitive portfolios aligned with evolving healthcare needs and business objectives.
Before joining Cipla, Satyen served as Senior Vice President at USV PRIVATE LIMITED, where he contributed to strategic business initiatives and portfolio expansion. Earlier, during his tenure at Alkem Laboratories Ltd., he played a pivotal role in Strategy, In-Licensing, and Business Development, driving portfolio growth through strategic partnerships, product acquisitions, and commercialization initiatives. His earlier experience at Ranbaxy saw him lead strategic marketing initiatives across multiple therapeutic areas, identifying therapy gaps, building robust product pipelines, and spearheading new product launches through in-licensing, outsourcing, and R&D collaborations.
With over two decades of experience spanning strategic marketing, portfolio management, business development, and global pharmaceutical strategy, Satyen brings a unique combination of commercial insight and strategic vision. His elevation to Chief Portfolio Head – Global reflects Cipla’s confidence in his leadership as the company continues to strengthen its global portfolio and accelerate sustainable growth across international markets.